| Mrs Ashley Andrew Lowery, NP | |
|
330 Brookline Ave, Boston, MA 02215-5400 | |
| (617) 667-3112 | |
| Not Available |
| Full Name | Mrs Ashley Andrew Lowery |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 330 Brookline Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598214603 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | RN271097 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Ashley Andrew Lowery, NP 54 Chippy Ln, Methuen, MA 01844-7427 Ph: (978) 273-5876 | Mrs Ashley Andrew Lowery, NP 330 Brookline Ave, Boston, MA 02215-5400 Ph: (617) 667-3112 |
News Archive
New findings explaining the complicated process by which the "energy substations" of human cells split apart and recombine may lay the groundwork for new treatment approaches to a wide range of diseases, including some cancers and neurodegenerative diseases such as Parkinson's and Alzheimer's.
A new study published in the November 19, 2019 issue of JAMA shows that a newly developed small molecule drug called ubrogepant may successfully fight migraine at doses of 25 and 50 mg, with pain relief at 2 hours with both doses, while the most troublesome symptom of migraine was held off at 2 hours post-dose with the 50 mg dose. This may help millions of migraine patients to achieve pain relief and function better.
People who have a birthweight over 10 pounds are twice as likely to develop rheumatoid arthritis when they are adults compared to individuals born with an average birthweight, according to a study published by researchers from Hospital for Special Surgery online in advance of print in the Annals of the Rheumatic Diseases. While the mechanism for this association is unclear, the study identifies a potentially modifiable risk factor and highlights a potential way to decrease the incidence of the disease.
In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.
› Verified 6 days ago
Roberta Louise Culbert-costley, APRN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-726-3700 | |
Jean Stewart, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-726-6988 | |
Ms. Kathleen Mary Breda, NP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-724-0578 | |
Ms. Ellen M Sinnott, RNCS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 386 W Broadway, 2nd Floor, Boston, MA 02127 Phone: 617-464-5875 Fax: 617-464-5878 | |
Sioban Haldeman, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-724-5110 Fax: 617-724-5150 | |
David John Becker, RN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 110 Stuart St Unit 18h, Boston, MA 02116 Phone: 508-641-8974 | |
Katherine G Scanlon, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 771 Albany St, Boston, MA 02118 Phone: 617-638-2825 |